Insight Molecular Diagnostics
IMDX
30 hedge funds and large institutions have $48.9M invested in Insight Molecular Diagnostics in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 5 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
0% more funds holding
Funds holding: 30 → 30 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
1% less capital invested
Capital invested by funds: $49.2M → $48.9M (-$322K)
2.88% less ownership
Funds ownership: 56.27% → 53.38% (-2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$660K |
| 2 |
Renaissance Technologies
New York
|
+$78.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$38.4K |
| 4 |
BlackRock
New York
|
+$20.9K |
| 5 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
+$15.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$2.81M |
| 2 |
WIA
Wealthedge Investment Advisors
New York
|
-$226K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$99.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$54K |
| 5 |
SG Americas Securities
New York
|
-$51K |
IMDX Hedge Fund Activity: Q2 2025 in Review
30 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2025, worth a combined $48.9M — down 0.65% from $49.2M a quarter earlier.
Fund positioning in IMDX was balanced in Q2 2025: 5 funds opened new positions, 5 closed out, 10 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $660K. The largest seller was Pura Vida Investments, cutting an estimated $2.81M.
- 30 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $48.9M of Insight Molecular Diagnostics stock for Q2 2025, down 0.65% quarter-over-quarter.
- 5 funds opened new Insight Molecular Diagnostics positions in Q2 2025 and 5 closed out, a net change of 0 holders.
- The largest Insight Molecular Diagnostics buyer in Q2 2025 was Vanguard Group, an estimated $660K added.
- The largest Insight Molecular Diagnostics seller in Q2 2025 was Pura Vida Investments, an estimated $2.81M sold.
Based on aggregated 13F filings for Q2 2025.